Apr 01, 2021

Improving Cancer Care and Outcomes in Our Communities

At its core, Huntsman Cancer Institute is dedicated to creating an environment that not only promotes—but insists upon—equity, diversity, and inclusion. Read highlights of noteworthy programs and research from the Cancer Control and Population Sciences Program that advance HCI’s quest to create a cancer-free frontier for all communities, no matter their location, income, or insurance status.

Apr 01, 2021

Banding Together to Advance Scientific Progress

When cancer researchers from different disciplines work together, they gain new insights into how cancer begins and how it can be treated. HCI is committed to providing an atmosphere where ideas can be created, cultivated, and shared. Here are some examples of how HCI scientists are collaborating to accelerate progress in cancer research.

Apr 01, 2021

Bringing Hope Closer to Cancer Patients

Clinical trials bring hope to patients in the form of innovative treatments. During the COVID-19 pandemic, despite strict hospital safety protocols and staff switching to remote work, HCI clinical research teams found a way to make sure patients could safely enroll and stay on clinical trials—remaining steadfast in our commitment to bring promising research advances to patients.

Apr 01, 2021

Reimagining Research in a Remote World

In March 2020, COVID-19 led to restrictions in on-site activities at HCI, at the University of Utah, across the state, and throughout the nation. HCI researchers were determined to keep labs functioning while also keeping employees safe. Learn how they overcame challenges and kept cancer research moving ahead.

Apr 01, 2021

Bridging the Gap for Promising New Drugs

The Accelerator at the University of Utah, headed by Dr. David Bearss, is working in conjunction with the Huntsman Cancer Institute, the College of Pharmacy, and the Partners for Innovation, Ventures, Outreach and Technology Center to break down the barriers investigators and researchers face in bringing new drugs and technologies to the public.

Apr 01, 2021

Working to Eradicate Cancer Through Research Innovation

Every five to seven years, HCI goes through a rigorous application process to maintain status as a National Cancer Institute-Designated Comprehensive Cancer Center and prove we meet the highest national standards for cancer care and research. In 2020, the NCI granted renewed status and awarded HCI its best score yet. And despite the challenges of the coronavirus pandemic in 2020, HCI submitted more research grants than the year before and kept clinical trials open for 1,800 patients.

Mar 23, 2021

New Guidance for Clinical Trial Participation by Cancer Patients Receiving a COVID-19 Vaccination

An international group of cancer clinical research experts reported new recommendations that receiving a COVID-19 vaccination should not preclude a cancer patient from participating on a clinical trial. Huntsman Cancer Institute physician-scientist and professor of internal medicine at the University of Utah, Neeraj Agarwal, MD, was part of this newly formed group who reviewed the data and provided recommendations to patients, doctors, research centers, and the pharmaceutical research industry on this critical, emerging issue.

Mar 03, 2021

Utah Researchers Illuminate Potential Precursors of Blood Cancers

Utah researchers report significant new insights into the development of blood cancers. Comparing DNA data in people with and without blood disorders, the researchers discovered genetic mutations in about 2% of the presumably healthy participants that were identical to those frequently observed in the cancer patients. These findings provide new clues about mutations that may initiate cancer development and those that may help cancer progress.